127 filings
Page 5 of 7
6-K
4b8b549 1b7r
25 Aug 20
Mereo BioPharma Announces Initiation of Placebo-Controlled Phase 1b/2 Clinical Trial with Alvelestat in COVID-19 Respiratory Disease
11:14am
6-K
pd6xjquq
3 Aug 20
Current report (foreign)
9:15am
6-K
jv3g9df
30 Jun 20
Result of Annual General Meeting
4:07pm
6-K
5tf53bv
16 Jun 20
Current report (foreign)
4:13pm
6-K
3fhj0hm kmdt4aod
9 Jun 20
Publication of Circular and Notice of General Meeting
4:15pm
6-K
9xzyh5z77wirk
5 Jun 20
Mereo BioPharma Announces Completion of $70 Million Private Placement
12:00am
6-K
lszm3b6
27 May 20
Notice of Annual General Meeting
7:37am
6-K
68tphuquigi8
22 May 20
Annual General Meeting
9:31am
6-K
db68j46e ssxfs8
28 Apr 20
Current report (foreign)
4:10pm
6-K
6a97mf0w
27 Mar 20
Business Update and Directorate Change
9:09am
6-K
v8pca3edz5qlpq9mjti8
28 Feb 20
Current report (foreign)
9:46am
6-K
lcvnh6
21 Feb 20
Current report (foreign)
4:30pm
6-K
gyq20
19 Feb 20
Mereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional Investor
9:32am
6-K
cbmqn132wnmc
18 Feb 20
Current report (foreign)
11:43am
6-K
4akml
12 Feb 20
Mereo Biopharma Announces Update on Distribution Related to Contingent Value Rights Following Recent Oncologie Licensing Agreement for Navicixizumab
9:48am
6-K
cowsh
10 Feb 20
Current report (foreign)
7:20am
6-K
y1w mvdyqm7l
14 Jan 20
Current report (foreign)
8:40am
6-K
vdg0eprliyi97a18 mb
13 Jan 20
Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab
8:26am
6-K
dwp dzvz2p
22 Nov 19
Current report (foreign)
9:29am
6-K
e2k qb8j1dpe4
7 Oct 19
Mereo BioPharma Receives FDA Fast Track Designation for Navicixizumab for the Treatment of Heavily Pretreated Ovarian Cancer
12:23pm